ERBB2 and breast cancer: Precision medicine addresses BC heterogeneity by utilizing PAM50 subtypes and risk of recurrence (ROR) scores to classify intrinsic molecular subtypes (Luminal A, Luminal B, HER2-enriched, Basal-like, or Normal-like) or recurrence risks [8,9].